CG Oncology (CGON) Stock Price, News & Analysis

Company Overview

CG Oncology, Inc. (NASDAQ: CGON) is a clinical-stage biotechnology company focused on developing therapies for bladder cancer. The company’s research is centered on treatments designed to stimulate the immune system and target tumors directly, with an emphasis on non-muscle-invasive bladder cancer (NMIBC).

Its lead investigational product, cretostimogene grenadenorep, also known as CG0070, is an intravesical oncolytic adenovirus intended for administration directly into the bladder. The therapy is designed to selectively replicate in cancer cells, promote tumor-cell destruction and stimulate an immune response through the production of granulocyte-macrophage colony-stimulating factor (GM-CSF). CG Oncology has evaluated the candidate in clinical studies involving patients with NMIBC, including disease that has not responded adequately to Bacillus Calmette-Guérin (BCG) treatment.

CG Oncology is headquartered in Irvine, California, and its activities are primarily focused on advancing its bladder-cancer pipeline through clinical development and regulatory evaluation. The company’s executive leadership includes Arthur Kuan, who serves as chief executive officer. As a development-stage biotechnology company, CG Oncology’s principal product candidate remains investigational and is subject to clinical and regulatory review.

Key Stats

• Today's Range: $71.86 to $77.79
• 50-Day Range: $69.12 to $80.68
• 52-Week Range: $35.64 to $80.97
• Volume: 830,942 shs
• Average Volume: 1.10 million shs
• Market Capitalization: $6.50 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $87.78
• Consensus Rating: Moderate Buy

CG Oncology Stock Analysis - MarketRank™

CG Oncology scored higher than 60% of companies evaluated by MarketBeat, and ranked 482nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CG Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

CG Oncology has a consensus price target of $87.78, representing about 19.7% upside from its current price of $73.36.

Amount of Analyst Coverage

CG Oncology has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CG Oncology are expected to grow in the coming year, from ($3.31) to ($3.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CG Oncology is -27.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CG Oncology is -27.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CG Oncology has a P/B Ratio of 7.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.50% of the float of CG Oncology has been sold short.

Short Interest Ratio / Days to Cover

CG Oncology has a short interest ratio ("days to cover") of 16.07, which indicates bearish sentiment.

Change versus previous month

Short interest in CG Oncology has recently increased by 1.31%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CG Oncology does not currently pay a dividend.

Dividend Growth

CG Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.79

News Sentiment

CG Oncology has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for CG Oncology this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for CGON on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $22,500,693.00 in company stock, which represents 0.3460% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, CG Oncology insiders have bought 972.47% more of their company's stock than they have sold. Specifically, they have bought $24,814,454.00 in company stock and sold $2,313,761.00 in company stock.

Percentage Held by Insiders

4.80% of the stock of CG Oncology is held by insiders.

Percentage Held by Institutions

26.56% of the stock of CG Oncology is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/23/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CGON
• Previous Symbol: NASDAQ:CGON
• CIK: 1991792
• Web: cgoncology.com
• Phone: (949) 409-3700
• Fax: N/A
• Employees: 142
• Year Founded: 2010

Price Target and Rating

• Average Price Target for CG Oncology: $87.78
• High Price Target: $100.00
• Low Price Target: $79.00
• Potential Upside/Downside: +19.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$160.99 million
• Net Margins: -3,602.68%
• Pretax Margin: -3,602.68%
• Return on Equity: -25.20%
• Return on Assets: -23.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.22
• Quick Ratio: 22.20

Sales & Book Value

• Annual Sales: $4.04 million
• Price / Sales: 1,609.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.33 per share
• Price / Book: 7.86

Miscellaneous

• Outstanding Shares: 88,640,000
• Free Float: 84,385,000
• Market Cap: $6.50 billion
• Optionable: Optionable
• Beta: 0.24